All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @pissandshit120 on TikTok · 9s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @pissandshit120's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00I'm just waiting for standing in here, just like a kid, and she's right on his death, on his death

@pissandshit120's GLP-1 journey video, fact-checked

radginger

TikTok creator

600.1K viewsWatch on TikTok

Quick answer

The transcript from this video contains no identifiable medical claim about GLP-1 receptor agonists or any other treatment. The video was categorized under GLP-1 medications, which include semaglutide and tirzepatide, but the spoken content as captured is not clinically interpretable. No clinical guidance, dosing information, or therapeutic assertion can be attributed to this creator based on the available transcript.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 9 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @pissandshit120's GLP-1 journey video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

@pissandshit120's GLP-1 journey video, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@pissandshit120's GLP-1 journey video, fact-checked" from radginger. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The transcript from this video contains no identifiable medical claim about GLP-1 receptor agonists or any other treatment.

The reason this review is not generic is the source wording and the canonical claim label "glp1 thank u for joining me on this journey credit pinofiles." In this clip, the useful excerpt is: "I'm just waiting for standing in here, just like a kid, and she's right on his death, on his death" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Semaglutide produced 14.
People who land here are usually comparing the GLP-1 social video fact-checks claim with [object Object].
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

The transcript from this video contains no identifiable medical claim about GLP-1 receptor agonists or any other treatment.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • The transcript from this video contains no identifiable medical claim about GLP-1 receptor agonists or any other treatment. The video was categorized under GLP-1 medications, which include semaglutide and tirzepatide, but the spoken content as captured is not clinically interpretable. No clinical guidance, dosing information, or therapeutic assertion can be attributed to this creator based on the available transcript.
  • This transcript contains no legible medical claim. No GLP-1 statement was made that can be confirmed or refuted.
  • Semaglutide produced 14.9% average weight loss vs 2.4% for placebo in the STEP 1 trial (Wilding et al., 2021, NEJM) at 2.4mg weekly dose in adults with obesity.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • This transcript contains no legible medical claim. No GLP-1 statement was made that can be confirmed or refuted.
  • Semaglutide produced 14.9% average weight loss vs 2.4% for placebo in the STEP 1 trial (Wilding et al., 2021, NEJM) at 2.4mg weekly dose in adults with obesity.
  • Tirzepatide showed up to 22.5% mean body weight reduction over 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), the largest effect seen in an approved weight-loss drug trial to date.
  • Compounded semaglutide or tirzepatide is not the same product as the FDA-approved branded drug. The FDA has stated compounded versions have not been evaluated for safety, efficacy, or quality.
  • The SELECT trial (Lincoff et al., 2023, NEJM) found cardiovascular benefit from semaglutide in patients with obesity and existing cardiovascular disease, but that benefit cannot be assumed to extend to all users or all formulations.
  • 600,000 views on a video with no legible health information is a reminder that social media reach is not a proxy for accuracy or safety.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @pissandshit120 actually say?

Honestly, there is not much to work with here. The transcript reads: "I'm just waiting for standing in here, just like a kid, and she's right on his death, on his death." That is the entirety of the spoken content. It is either severely garbled audio, auto-caption failure, or a clip that was cut so aggressively that no coherent claim survives. No medical statement, no GLP-1 reference, no dosing claim, nothing actionable was captured.

The video has 600,000 views and sits in the GLP-1 category, which means the platform or the tagger flagged it as relevant to drugs like semaglutide or tirzepatide. But flagging a category and making a claim are two different things. We cannot fact-check a sentence that does not make a sentence.

Does the science back this up?

There is no claim here to test against the literature. What we can do is note what the science actually says about GLP-1 receptor agonists, since that is the category this video was filed under, and since 600,000 people watched it for some reason.

GLP-1 receptor agonists like semaglutide and tirzepatide have strong clinical trial support for weight reduction and glycemic control. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed tirzepatide producing up to 22.5% mean body weight reduction over 72 weeks. The STEP 1 trial (Wilding et al., 2021, NEJM) showed semaglutide at 2.4mg producing roughly 14.9% weight loss versus 2.4% with placebo. These are real, peer-reviewed results from large randomized controlled trials. The drugs work. That is not in dispute.

What is also not in dispute: side effect profiles are significant, access is uneven, compounded versions are not equivalent to branded formulations, and the long-term cardiovascular and oncological data is still accumulating.

What did they get wrong (or right)?

Neither. The transcript contains no falsifiable claim. The creator said something that the caption system rendered as word salad, and we have no way of knowing what they actually meant to communicate. That is not a pass, by the way. A 600,000-view video in a regulated drug category that produces zero legible information is its own kind of problem.

The credit given to @pinofiles in the caption suggests this may be a reaction video or a repurposed clip, which could explain the incoherence. But that does not change what viewers consumed. If someone watched this video expecting GLP-1 guidance and walked away with anything at all, that information came from somewhere other than this transcript, possibly the comments, possibly prior videos, possibly their own projection.

We cannot give credit or assign fault to claims that do not exist in verifiable form. What we can say plainly is that this is not a source anyone should use to make decisions about semaglutide, tirzepatide, or any other regulated medication.

What should you actually know?

GLP-1 receptor agonists are serious medications with real clinical evidence behind them and real risks that require medical supervision. Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are FDA-approved for specific indications. They are not interchangeable with compounded peptides, and compounded versions have not undergone the same manufacturing and efficacy review as branded drugs.

Common side effects include nausea, vomiting, gastroparesis-adjacent slowing, and in rare cases pancreatitis. The SELECT trial (Lincoff et al., 2023, NEJM) showed cardiovascular benefit in adults with obesity and established cardiovascular disease, which is meaningful. But that finding applies to the studied drug at the studied dose in the studied population, not to whatever someone is ordering from a compounding pharmacy based on a TikTok video they half-watched.

If you are considering a GLP-1 medication, talk to a licensed clinician. A 600,000-view TikTok with an unreadable transcript is not a substitute for a medical consultation, a prescription, or a safety screening.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

radginger · TikTok creator

600.1K views on this video

thank u for joining me on this journey credit @pinofiles

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about this transcript contains no legible medical claim. no glp-1 statement?

This transcript contains no legible medical claim. No GLP-1 statement was made that can be confirmed or refuted.

What does the video say about semaglutide produced 14.9% average weight loss vs 2.4% for placebo?

Semaglutide produced 14.9% average weight loss vs 2.4% for placebo in the STEP 1 trial (Wilding et al., 2021, NEJM) at 2.4mg weekly dose in adults with obesity.

What does the video say about tirzepatide showed up to 22.5% mean body weight reduction over?

Tirzepatide showed up to 22.5% mean body weight reduction over 72 weeks in SURMOUNT-1 (Jastreboff et al., 2022, NEJM), the largest effect seen in an approved weight-loss drug trial to date.

What does the video say about compounded semaglutide?

Compounded semaglutide or tirzepatide is not the same product as the FDA-approved branded drug. The FDA has stated compounded versions have not been evaluated for safety, efficacy, or quality.

What does the video say about the select trial (lincoff et al., 2023, nejm) found cardiovascular?

The SELECT trial (Lincoff et al., 2023, NEJM) found cardiovascular benefit from semaglutide in patients with obesity and existing cardiovascular disease, but that benefit cannot be assumed to extend to all users or all formulations.

What does the video say about 600,000 views on a video with no legible health information?

600,000 views on a video with no legible health information is a reminder that social media reach is not a proxy for accuracy or safety.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by radginger, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.